Developer docs
API playgroundTry for free, no card

Search company profiles

Anokion

Full company profile

uuid0004hnt

Namestring
Anokion
Websiteurl
anokion.com
Company typeenum
Private
Founded yearint
2010
Short descriptiontext

Anokion is a clinical-stage Swiss biotechnology company developing an immune tolerance platform, with its lead drug candidate KAN-101 in Phase 2 clinical trials for celiac disease, an autoimmune disorder with no approved pharmacological therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEcublens, Switzerland
HQ citystring
Ecublens
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune tolerance therapy, autoimmune disease treatment, clinical-stage biotechnology, celiac disease therapy, antigen-specific immunotherapy
Industry2 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing proprietary drug candidates for autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

finsmes.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anokion is a clinical-stage biotechnology company developing proprietary immune tolerance therapeutics for autoimmune diseases. The company's lead drug candidate, KAN-101, is in Phase 2 clinical development for the treatment of celiac disease. The platform is built around harnessing natural immune equilibrium to induce antigen-specific immune tolerance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2 clinical trial enrollment for KAN-101 in celiac disease
Product and service1 record
1KAN-101
CategoryBiopharmaceutical / Immunotherapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

AbbVie is a global immunology leader (Humira, Skyrizi, Rinvoq) and a potential strategic acquirer of immune tolerance platforms like Anokion's. As a broad incumbent, it shapes competitive dynamics and M&A benchmarks for autoimmune-focused biotechs.

2Selecta Biosciences
TypeDirect peer
Description

Selecta Biosciences is developing antigen-specific immune tolerance therapies using ImmTOR and SEL-302 platforms. It is directly comparable to Anokion because both pursue immune tolerance as a core platform approach to autoimmune disease.

TypeBroad incumbent
Description

Takeda acquired PvP Biologics and is advancing TAK-062 (latiglutenase) for celiac disease. As a large pharmaceutical company with multiple celiac programs and established autoimmune infrastructure, Takeda is a broad incumbent peer to Anokion in celiac specifically.

TypeDirect peer
Description

Immunic Therapeutics is developing IMU-856 for celiac disease and has other autoimmune programs in IBD and multiple sclerosis. It is one of the closest direct comparables to Anokion in terms of indication focus, development stage, and disease-modifying mechanism.

TypeBroad incumbent
Description

Pfizer is both a strategic investor and board participant in Anokion and a major immunology player. As a broad incumbent with autoimmune assets, Pfizer shapes both partnership economics and competitive benchmarks for celiac and adjacent indications.

TypeDirect peer
Description

COUR Pharmaceuticals develops antigen-specific immune tolerance therapies for autoimmune diseases, including celiac disease. Its platform and target indications overlap materially with Anokion's KAN-101 approach.

TypeDirect peer
Description

9 Meters Biopharma has been developing larazotide (NM-002) for celiac disease, a tight-junction modulator addressing the same indication as KAN-101. It is a direct competitor for celiac patients and provider attention.

TypeEmerging player
Description

AnaptysBio develops antibody-based therapeutics for inflammatory and autoimmune diseases. Although it uses a different modality, it targets overlapping indications and competes for autoimmune development talent and capital relevant to Anokion's expansion roadmap.

TypeBroad incumbent
Description

Sanofi operates a major immunology franchise (Dupixent) and pursues antigen-specific and immune-modulating therapies. It is comparable to Anokion as a broad incumbent competing for autoimmune patient share and as a potential strategic acquirer of platform biotechs.

TypeEmerging player
Description

Provention Bio develops immune-mediated disease therapies, including work in celiac and type 1 diabetes. It shares Anokion's focus on autoimmune diseases with antigen- or immune-modulating mechanisms but operates at a more commercial stage.

Market position
Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anokion

Biopharmaceuticals / Immunotherapyanokion.com

Anokion is a clinical-stage Swiss biotechnology company developing an immune tolerance platform, with its lead drug candidate KAN-101 in Phase 2 clinical trials for celiac disease, an autoimmune disorder with no approved pharmacological therapy.

Anokion firmographics

Firmographics
Name
Anokion
Website
https://anokion.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Anokion is a clinical-stage Swiss biotechnology company developing an immune tolerance platform, with its lead drug candidate KAN-101 in Phase 2 clinical trials for celiac disease, an autoimmune disorder with no approved pharmacological therapy.
Ownership category
akta.pro rank

Anokion industry classification

Industry
Product category
Biopharmaceuticals / Immunotherapy
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Immune tolerance therapy
  • Autoimmune disease treatment
  • Clinical-stage biotechnology
  • Celiac disease therapy
  • Antigen-specific immunotherapy

Where Anokion is headquartered

Location

Headquarters

HQ city
Ecublens
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Anokion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing proprietary drug candidates for autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels2 records

Anokion product offering

Product offering

Core offering

Anokion is a clinical-stage biotechnology company developing proprietary immune tolerance therapeutics for autoimmune diseases. The company's lead drug candidate, KAN-101, is in Phase 2 clinical development for the treatment of celiac disease. The platform is built around harnessing natural immune equilibrium to induce antigen-specific immune tolerance.

Differentiator

Problem solved

Functional benefit

Products and services

  • KAN-101

Quantifiable outcome

  • Phase 2 clinical trial enrollment for KAN-101 in celiac disease

Companies that use Anokion

Customer profile

Segments2 records

Ideal customer profiles1 record

Anokion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Anokion partnerships and signals

Strategic signal

Scale indicators3 records

Anokion competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie is a global immunology leader (Humira, Skyrizi, Rinvoq) and a potential strategic acquirer of immune tolerance platforms like Anokion's. As a broad incumbent, it shapes competitive dynamics and M&A benchmarks for autoimmune-focused biotechs.
  • Takeda Pharmaceutical: Takeda acquired PvP Biologics and is advancing TAK-062 (latiglutenase) for celiac disease. As a large pharmaceutical company with multiple celiac programs and established autoimmune infrastructure, Takeda is a broad incumbent peer to Anokion in celiac specifically.
  • Pfizer: Pfizer is both a strategic investor and board participant in Anokion and a major immunology player. As a broad incumbent with autoimmune assets, Pfizer shapes both partnership economics and competitive benchmarks for celiac and adjacent indications.
  • Sanofi: Sanofi operates a major immunology franchise (Dupixent) and pursues antigen-specific and immune-modulating therapies. It is comparable to Anokion as a broad incumbent competing for autoimmune patient share and as a potential strategic acquirer of platform biotechs.

Direct peers

  • Selecta Biosciences: Selecta Biosciences is developing antigen-specific immune tolerance therapies using ImmTOR and SEL-302 platforms. It is directly comparable to Anokion because both pursue immune tolerance as a core platform approach to autoimmune disease.
  • Immunic Therapeutics: Immunic Therapeutics is developing IMU-856 for celiac disease and has other autoimmune programs in IBD and multiple sclerosis. It is one of the closest direct comparables to Anokion in terms of indication focus, development stage, and disease-modifying mechanism.
  • COUR Pharmaceuticals: COUR Pharmaceuticals develops antigen-specific immune tolerance therapies for autoimmune diseases, including celiac disease. Its platform and target indications overlap materially with Anokion's KAN-101 approach.
  • 9 Meters Biopharma: 9 Meters Biopharma has been developing larazotide (NM-002) for celiac disease, a tight-junction modulator addressing the same indication as KAN-101. It is a direct competitor for celiac patients and provider attention.

Emerging players

  • AnaptysBio: AnaptysBio develops antibody-based therapeutics for inflammatory and autoimmune diseases. Although it uses a different modality, it targets overlapping indications and competes for autoimmune development talent and capital relevant to Anokion's expansion roadmap.
  • Provention Bio: Provention Bio develops immune-mediated disease therapies, including work in celiac and type 1 diabetes. It shares Anokion's focus on autoimmune diseases with antigen- or immune-modulating mechanisms but operates at a more commercial stage.

Market position

Customer concentration

Anokion social profiles

Digital presence

Anokion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anokion leadership team

Management profile

Number of profiles

Profiles6 records

Anokion funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anokion M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anokion

What does Anokion do?

Anokion is a clinical-stage biotechnology company developing proprietary immune tolerance therapeutics for autoimmune diseases. The company's lead drug candidate, KAN-101, is in Phase 2 clinical development for the treatment of celiac disease. The platform is built around harnessing natural immune equilibrium to induce antigen-specific immune tolerance.

Is Anokion a public or private company?

Anokion is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anokion founded?

Anokion was founded in 2010. It employs 11 to 50 people.

Where is Anokion based?

Anokion is headquartered in Ecublens, Switzerland, in the Europe region.

How does Anokion make money?

One revenue line is on record: drug Development and Commercialization.

Who are Anokion's main competitors?

Broad incumbents on record are AbbVie, Takeda Pharmaceutical, Pfizer and Sanofi. Direct peers are Selecta Biosciences, Immunic Therapeutics, COUR Pharmaceuticals and 9 Meters Biopharma. Emerging players are AnaptysBio and Provention Bio.

Does Anokion have an API?

No public API is recorded for Anokion.

What industry is Anokion in?

Anokion's product category is Biopharmaceuticals / Immunotherapy. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCarisma Therapeutics Announces Changes to its Board of DirectorsCarisma Therapeutics Inc. announced the appointment of John Hohneker, M.D. to its Board of Directors, effective April 1, 2024, along with the resignation of Chidozie Ugwumba from the Board and Audit Committee. Dr. Hohneker brings over 30 years of drug development experience, having previously served as CEO of Anokion SA and President of R&D at FORMA Therapeutics Inc. The company characterized the change as a routine governance update, with Chair Sanford Zweifach stating the new director's experience in clinical development and public company board membership will support the company's engineered macrophage development programs.BioSpaceAnokion Announces Clinical Progress with KAN-101 and ANK-700Anokion announced Phase 2 dosing for KAN-101 in celiac disease and completed enrollment in its ANK-700 multiple sclerosis trial. The company expects topline data for KAN-101 in 2024 and full results for ANK-700 in the second half of 2024.startupticker.chPfizer invests $35 million in AnokionPfizer has made a $35 million equity investment in clinical-stage biotech Anokion and partnered to advance the development of its lead candidate KAN-101 for celiac disease. The capital will support Anokion's upcoming Phase 2 clinical trials, which follow favorable safety and biomarker data from Phase 1 studies. Pfizer experts have also joined Anokion’s advisory and boards to assist with the drug's continued development.ContractpharmaPfizer Invests $35M in Anokion and Celiac Disease CandidatePfizer invested $35 million in Anokion and agreed to fund its Phase 2 clinical program of KAN-101 for celiac disease. The company plans to initiate patient dosing in the second half of 2022, based on favorable Phase 1 data showing safety and reduced T cell responses.FinSMEsAnokion Raises $35M in Equity Funding from PfizerAnokion, a Lausanne-based clinical-stage biotechnology company, raised $35 million in equity funding led by Pfizer Breakthrough Growth Initiative. The investment includes an agreement for Pfizer to support the clinical development of Anokion's lead candidate KAN-101 for celiac disease, with Pfizer executives joining Anokion's advisory and boards. Anokion intends to use the proceeds to fund its Phase 2 clinical program for this autoimmune disorder.Business Wire BlogAnokion Announces $35 Million Equity Investment from PfizerAnokion announced a $35 million equity investment from Pfizer to support the advancement of its candidate KAN-101 for celiac disease into Phase 2 clinical development. As part of the investment, Pfizer's representatives will join Anokion's scientific advisory board and board of directors. The funding aims to provide necessary resources and expertise for developing treatment options for patients with autoimmune diseases like celiac disease.FierceBiotechAnokion autoimmune pact rides out BMS-Celgene mergerBristol Myers Squibb and Celgene are expanding their partnership with Anokion to include celiac disease and multiple sclerosis programs. The deal adds KAN-101 for celiac and ANK-700 for MS, with Anokion handling preclinical and phase 1 development. BMS will take over subsequent trials and commercial activities.FinSMEsAnokion Raises $40M; Acquires Kanyos BioAnokion SA raised $40M in a Series B led by Versant Ventures, Novartis Venture Fund, Novo Ventures, and select Swiss investors, with Celgene participating. The company, which has raised over $160M, will use the funds to advance its pipeline, including the acquisition of Kanyos Bio's KAN-101 for celiac disease, with an IND expected by end of 2019.startupticker.chAnokion Announces Exclusive Strategic Collaboration with CelgeneAnokion announced an exclusive global research collaboration with Celgene to develop tolerance-inducing therapeutics for autoimmune diseases. Celgene paid $45 million upfront and is eligible for an additional $10 million, and obtained an equity interest and exclusive acquisition rights. Anokion retains full control of its R&D during the option period.